Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it has created a Clinical Advisory Board (“CAB”). The company has named world-renowned medical and clinical experts as the board’s first members. The purpose of the board is to provide expert guidance for Genprex’s novel gene therapy clinical development programs in cancer and diabetes. More specifically, CAB members will provide invaluable guidance and advise as Genprex advances its REQORSA(TM) (“REQORSA”) immunogene therapy program and its preclinical diabetes gene therapy program. Board members include the following: Michael Morse, MD, MHS, FACP; Col. George E. Peoples, MD, FACS; Andrew B. Becker, MD, PhD; and William E. Gannon, Jr., MD, MBA. Genprex also has entered into securities purchase agreements with two healthcare-dedicated institutional investors. Expected to close on or about Feb. 11, 2021, the agreements outline the purchase and sale of 4 million shares of GNPX common stock at a purchase price of $6.25 per share in a registered direct offering; the agreements are priced at-the-market under Nasdaq rules. “We are pleased to bring together this group of seasoned practitioners in the field of oncology and diabetes to guide and advise Genprex in advancing our clinical development programs,” said Genprex’s CEO Rodney Varner in the press release. “The Clinical Advisory Board’s experience in clinical trials of cancer and diabetes therapies, combined with their expertise in consulting with small and large biotechnology companies, is invaluable as our drug candidates progress into the clinic.”
To view the full press releases, visit https://ibn.fm/ALIpH and https://ibn.fm/J3TxJ
About Genprex Inc.
Genprex is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted fast track designation for REQORSA for NSCLC (“NSCLC”) in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR (“EFGR”) mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php